{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:46:43Z","timestamp":1783637203920,"version":"3.55.0"},"reference-count":117,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":146,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KU Leuven Internal Funds","award":["C24\/18\/095"],"award-info":[{"award-number":["C24\/18\/095"]}]},{"name":"Research on Ageing and Mental Health"},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["PDMT2\/24\/089"],"award-info":[{"award-number":["PDMT2\/24\/089"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Synaptic loss is an early hallmark of many neurological disorders, including Alzheimer\u2019s disease, but also occurs in aging brains as evidenced by PET- and CSF-based biomarker studies. This cross-sectional study investigates how blood-based synaptic proteins and other biomarkers relate to synaptic density in brains of older adults without dementia, and how these associations are mediated by gray matter (GM) loss. Plasma levels of synaptic biomarkers including synaptosomal-associated protein of 25\u2005kDa and vesicle-associated membrane protein 2 as well as amyloid, tau, neurodegeneration and neuroinflammation (ATN(I)) biomarkers including the amyloid-\u03b21-42\/amyloid-\u03b21-40 ratio, phosphorylated tau181, neurofilament light and glial fibrillary acidic protein were quantified in 61 older adults without dementia [mean age \u00b1 standard deviation = 71 \u00b1 6 years, median Mini-Mental State Examination score (interquartile range) = 29 (3), 64% female, 38% late-life depression] who underwent synaptic vesicle glycoprotein 2A PET and T1-weighted MRI. Subsets underwent amyloid (n = 49) and tau (n = 52) PET. The study population demonstrated limited PET-based amyloid-\u03b2 and tau pathology, which did not associate with any of the investigated plasma biomarkers. Synaptic plasma biomarkers correlated with each other [Spearman\u2019s \u03c1 (95% confidence interval) 0.37 (0.14\u20130.57), P = 0.019], but not with the ATN(I) plasma biomarkers. Plasma vesicle-associated membrane protein 2 associated with synaptic vesicle glycoprotein 2A PET within frontal, temporal, and occipital cortices [\u03b2s (95% confidence interval) \u22120.75 (\u22121.06 to \u22120.44)], independent of age. Glial fibrillary acidic protein also demonstrated associations with synaptic vesicle glycoprotein 2A PET, particularly within temporal regions, the cingulate gyrus, and the precuneus [\u03b2s (95% confidence interval) \u22120.30 (\u22120.48 to \u22120.12)] when corrected for age and additionally within the caudate nucleus and thalamus when not [\u03b2s (95% confidence interval) \u22120.45 (\u22120.64 to \u22120.25)]. Similar associations were found in subgroups without, respectively, Alzheimer\u2019s disease pathology, or late-life depression (with cognitive impairment). No associations with synaptic vesicle glycoprotein 2A PET were found for synaptosomal-associated protein of 25\u2005kDa, phosphorylated tau181, neurofilament light or amyloid-\u03b21-42\/amyloid-\u03b21-40, likely due to the minimal presence of Alzheimer\u2019s disease pathology in the study population. GM volume associated with glial fibrillary acidic protein [\u03b2s (95% confidence interval) \u22120.15 (\u22120.25 to \u22120.05)] and partially (29%) mediated its association with synaptic vesicle glycoprotein 2A PET. In conclusion, plasma levels of glial fibrillary acidic protein and vesicle-associated membrane protein 2 may reflect synapse pathology independent of age and beyond general neuronal loss, even in absence of detectable Alzheimer\u2019s disease pathology.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf207","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T20:01:54Z","timestamp":1748289714000},"source":"Crossref","is-referenced-by-count":3,"title":["Plasma vesicle-associated membrane protein 2 and glial fibrillary acidic protein associate with synaptic density in older adults without dementia"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6729-7601","authenticated-orcid":false,"given":"Steffi","family":"De Meyer","sequence":"first","affiliation":[{"name":"Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Alali","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Laroy","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vande Casteele","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"University Psychiatric Centre (UPC), Department of Geriatric Psychiatry, KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Van Cauwenberge","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"Neurology Department, UZ Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Goossens","sequence":"additional","affiliation":[{"name":"ADx NeuroSciences NV , 9052 Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"De Rocker","sequence":"additional","affiliation":[{"name":"ADx NeuroSciences NV , 9052 Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Vanbrabant","sequence":"additional","affiliation":[{"name":"ADx NeuroSciences NV , 9052 Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[{"name":"ADx NeuroSciences NV , 9052 Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-3195","authenticated-orcid":false,"given":"Jan","family":"Van den Stock","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"University Psychiatric Centre (UPC), Department of Geriatric Psychiatry, KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Bouckaert","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"University Psychiatric Centre (UPC), Department of Geriatric Psychiatry, KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"Division of Nuclear Medicine, UZ Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vandenbulcke","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"University Psychiatric Centre (UPC), Department of Geriatric Psychiatry, KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0011-4158","authenticated-orcid":false,"given":"Louise","family":"Emsell","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"University Psychiatric Centre (UPC), Department of Geriatric Psychiatry, KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"Translational MRI, Department of Imaging and Pathology, KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5290-9476","authenticated-orcid":false,"given":"Koen","family":"Poesen","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven , 3000 Leuven ,","place":["Belgium"]},{"name":"Laboratory Medicine, UZ Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"4","key":"2025082607522332800_fcaf207-B1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrn3200","article-title":"The ageing cortical synapse: Hallmarks and implications for cognitive decline","volume":"13","author":"Morrison","year":"2012","journal-title":"Nat Rev Neurosci"},{"key":"2025082607522332800_fcaf207-B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2016.04.005","article-title":"Synaptic pathology: A shared mechanism in neurological disease","volume":"28","author":"Henstridge","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"3","key":"2025082607522332800_fcaf207-B3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2018.10.018","article-title":"Activity-induced amyloid-\u03b2 oligomers drive compensatory synaptic rearrangements in brain circuits controlling memory of presymptomatic Alzheimer\u2019s disease mice","volume":"86","author":"Pignataro","year":"2019","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2025082607522332800_fcaf207-B4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3233\/JAD-160845","article-title":"Synaptic compensation as a probable cause of prolonged mild cognitive impairment in Alzheimer\u2019s disease: Implications from a transgenic mouse model of the disease","volume":"56","author":"Baazaoui","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2025082607522332800_fcaf207-B5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcdb.2022.05.028","article-title":"Synapse pathology in Alzheimer\u2019s disease","volume":"139","author":"Griffiths","year":"2023","journal-title":"Semin Cell Dev Biol"},{"issue":"3 Suppl","key":"2025082607522332800_fcaf207-B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JAD-2006-9S311","article-title":"Synaptic remodeling during aging and in Alzheimer\u2019s disease","volume":"9","author":"Masliah","year":"2006","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2025082607522332800_fcaf207-B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrn1809","article-title":"Neural plasticity in the ageing brain","volume":"7","author":"Burke","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"22","key":"2025082607522332800_fcaf207-B8","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1523\/JNEUROSCI.6410-09.2010","article-title":"Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment","volume":"30","author":"Dumitriu","year":"2010","journal-title":"J Neurosci"},{"issue":"5896","key":"2025082607522332800_fcaf207-B9","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1126\/science.1162844","article-title":"Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer\u2019s disease","volume":"321","author":"Busche","year":"2008","journal-title":"Science"},{"issue":"11","key":"2025082607522332800_fcaf207-B10","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","article-title":"Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway","volume":"27","author":"Shankar","year":"2007","journal-title":"J Neurosci"},{"issue":"4","key":"2025082607522332800_fcaf207-B11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer\u2019s disease: Synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann Neurol"},{"issue":"18","key":"2025082607522332800_fcaf207-B12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","article-title":"Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment","volume":"68","author":"Scheff","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"2025082607522332800_fcaf207-B13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.nbd.2011.10.016","article-title":"Synaptic dysfunction in progranulin-deficient mice","volume":"45","author":"Petkau","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"11","key":"2025082607522332800_fcaf207-B14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","article-title":"Synaptic proteins predict cognitive decline in Alzheimer\u2019s disease and Lewy body dementia","volume":"12","author":"Bereczki","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B15","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1038\/s41598-024-53093-1","article-title":"Dopaminergic neuron loss in mice due to increased levels of wild-type human \u03b1-synuclein only takes place under conditions of accelerated aging","volume":"14","author":"Perez-Villalba","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"2025082607522332800_fcaf207-B16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jnen\/60.5.403","article-title":"Cortical synapse loss in progressive supranuclear palsy","volume":"60","author":"Bigio","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"2025082607522332800_fcaf207-B17","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/alz.12894","article-title":"Synaptic resilience is associated with maintained cognition during ageing","volume":"19","author":"King","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"348","key":"2025082607522332800_fcaf207-B18","doi-asserted-by":"crossref","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","article-title":"Imaging synaptic density in the living human brain","volume":"8","author":"Finnema","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"2025082607522332800_fcaf207-B19","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/alz.13720","article-title":"Tracing synaptic loss in Alzheimer\u2019s brain with SV2A PET-tracer UCB-J","volume":"20","author":"Kumar","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00401-024-02816-9","article-title":"Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: A comparative analysis with synaptophysin and ground truth for PET-imaging interpretation","volume":"148","author":"Shanaki Bavarsad","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2025082607522332800_fcaf207-B21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00259-023-06487-8","article-title":"The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: In vivo PET measurement with [11C]UCB-J","volume":"51","author":"Toyonaga","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025082607522332800_fcaf207-B22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2967\/jnumed.119.228080","article-title":"Characterization of 3 PET tracers for quantification of mitochondrial and synaptic function in healthy human brain: 18F-BCPP-EF, 11C-SA-4503, and 11C-UCB-J","volume":"61","author":"Mansur","year":"2020","journal-title":"J Nucl Med"},{"issue":"10","key":"2025082607522332800_fcaf207-B23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"2025082607522332800_fcaf207-B24","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1212\/WNL.0000000000009818","article-title":"In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment","volume":"95","author":"Vanhaute","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"2025082607522332800_fcaf207-B25","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/mds.28617","article-title":"Reduced synaptic density in patients with Lewy body dementia: An [11C]UCB-J PET imaging study","volume":"36","author":"Andersen","year":"2021","journal-title":"Mov Disord"},{"issue":"1","key":"2025082607522332800_fcaf207-B26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41824-020-00093-9","article-title":"11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies","volume":"4","author":"Nicastro","year":"2020","journal-title":"Eur J Hybrid Imaging"},{"issue":"11","key":"2025082607522332800_fcaf207-B27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/mds.28216","article-title":"Loss of presynaptic terminal integrity in the substantia Nigra in early Parkinson\u2019s disease","volume":"35","author":"Delva","year":"2020","journal-title":"Mov Disord"},{"issue":"3","key":"2025082607522332800_fcaf207-B28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ana.25682","article-title":"Synaptic changes in Parkinson disease assessed with in vivo imaging","volume":"87","author":"Matuskey","year":"2020","journal-title":"Ann Neurol"},{"key":"2025082607522332800_fcaf207-B29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neurobiolaging.2021.01.016","article-title":"In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies","volume":"101","author":"Mak","year":"2021","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2025082607522332800_fcaf207-B30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ana.26543","article-title":"Synaptic loss in frontotemporal dementia revealed by [11 C]UCB-J positron emission tomography","volume":"93","author":"Malpetti","year":"2023","journal-title":"Ann Neurol"},{"issue":"1","key":"2025082607522332800_fcaf207-B31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-023-01336-0","article-title":"Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer\u2019s disease continuum","volume":"15","author":"Goossens","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2025082607522332800_fcaf207-B32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","article-title":"Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease","volume":"15","author":"Schindler","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13195-022-01021-8","article-title":"Quantification of SNAP-25 with mass spectrometry and Simoa: A method comparison in Alzheimer\u2019s disease","volume":"14","author":"Nilsson","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"2025082607522332800_fcaf207-B34","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/brain\/awae032","article-title":"Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases","volume":"147:","author":"Nilsson","year":"2024","journal-title":"Brain"},{"issue":"21","key":"2025082607522332800_fcaf207-B35","doi-asserted-by":"crossref","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","article-title":"CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: A cross-sectional study","volume":"97","author":"Mil\u00e0-Alom\u00e0","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"2025082607522332800_fcaf207-B36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","article-title":"Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer\u2019s disease and frontotemporal dementia","volume":"15","author":"Das","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2025082607522332800_fcaf207-B37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-024-01409-8","article-title":"The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer\u2019s disease","volume":"16","author":"Das","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2025082607522332800_fcaf207-B38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","article-title":"Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid","volume":"18","author":"Lle\u00f3","year":"2019","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"2025082607522332800_fcaf207-B39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13195-025-01685-y","article-title":"Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer\u2019s pathophysiological biomarkers","volume":"17","author":"Gonz\u00e1lez","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2025082607522332800_fcaf207-B40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-019-0564-2","article-title":"CSF synaptic protein concentrations are raised in those with atypical Alzheimer\u2019s disease but not frontotemporal dementia","volume":"11","author":"Clarke","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2025082607522332800_fcaf207-B41","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1212\/WNL.0000000000207371","article-title":"CSF synaptic biomarkers in AT(N)-based subgroups of Lewy body disease","volume":"101","author":"Barba","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"2025082607522332800_fcaf207-B42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-022-01002-x","article-title":"Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"14","author":"Kivis\u00e4kk","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2025082607522332800_fcaf207-B43","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/alz.12809","article-title":"Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"19","author":"Nilsson","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13195-020-00655-w","article-title":"CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer\u2019s disease","volume":"12","author":"Mouton-Liger","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"2025082607522332800_fcaf207-B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.12.047","article-title":"Differential distribution of neuregulin in human brain and spinal fluid","volume":"1258","author":"Pankonin","year":"2009","journal-title":"Brain Res"},{"issue":"1","key":"2025082607522332800_fcaf207-B46","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41467-020-15270-4","article-title":"Different regions of synaptic vesicle membrane regulate VAMP2 conformation for the SNARE assembly","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"2025082607522332800_fcaf207-B47","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease","volume":"11","author":"De Vos","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pro.3307","article-title":"The human protein atlas: A spatial map of the human proteome","volume":"27","author":"Thul","year":"2018","journal-title":"Protein Sci"},{"issue":"3","key":"2025082607522332800_fcaf207-B49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","article-title":"Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2020","journal-title":"J Proteome Res"},{"issue":"4","key":"2025082607522332800_fcaf207-B50","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/alz.12790","article-title":"Relationship of serum beta-synuclein with blood biomarkers and brain atrophy","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2025082607522332800_fcaf207-B51","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1002\/alz.13103","article-title":"Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2025082607522332800_fcaf207-B52","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1002\/alz.13046","article-title":"Blood \u03b2-synuclein is related to amyloid PET positivity in memory clinic patients","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-022-01014-7","article-title":"Plasma neuregulin 1 as a synaptic biomarker in Alzheimer\u2019s disease: A discovery cohort study","volume":"14","author":"Vrillon","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"2025082607522332800_fcaf207-B54","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1002\/alz.13084","article-title":"Plasma ATN(I) classification and precision pharmacology in Alzheimer\u2019s disease","volume":"19","author":"Imbimbo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2025082607522332800_fcaf207-B55","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025082607522332800_fcaf207-B56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12888-021-03063-y","article-title":"The Leuven late life depression (L3D) study: PET-MRI biomarkers of pathological brain ageing in late-life depression: Study protocol","volume":"21","author":"Emsell","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"Suppl 20","key":"2025082607522332800_fcaf207-B57","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"2025082607522332800_fcaf207-B58","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/0271678X221076023","article-title":"Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls","volume":"42","author":"Mertens","year":"2022","journal-title":"J Cereb Blood Flow Metab"},{"key":"2025082607522332800_fcaf207-B59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jagp.2024.07.005","article-title":"Late life depression is not associated with Alzheimer-type tau: Preliminary evidence from a next-generation tau ligand PET-MR study","volume":"33","author":"Vande Casteele","year":"2025","journal-title":"Am J Geriatr Psychiatry"},{"key":"2025082607522332800_fcaf207-B60","doi-asserted-by":"crossref","first-page":"102707","DOI":"10.1016\/j.nicl.2021.102707","article-title":"Icobrain ms 5.1: Combining unsupervised and supervised approaches for improving the detection of multiple sclerosis lesions","volume":"31","author":"Raki\u0107","year":"2021","journal-title":"NeuroImage Clin"},{"issue":"1","key":"2025082607522332800_fcaf207-B61","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.nicl.2013.04.001","article-title":"Polymorphism of brain derived neurotrophic factor influences \u03b2 amyloid load in cognitively intact apolipoprotein E \u025b4 carriers","volume":"2","author":"Adamczuk","year":"2013","journal-title":"NeuroImage Clin"},{"issue":"1","key":"2025082607522332800_fcaf207-B62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13195-021-00798-4","article-title":"Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults","volume":"13","author":"Schaeverbeke","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"2025082607522332800_fcaf207-B63","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1093\/brain\/awab335","article-title":"Changes in the language system as amyloid-\u03b2 accumulates","volume":"144","author":"Reinartz","year":"2021","journal-title":"Brain"},{"issue":"1","key":"2025082607522332800_fcaf207-B64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","article-title":"Amyloid imaging in cognitively normal older adults: Comparison between 18F-flutemetamol and 11C-Pittsburgh compound B","volume":"43","author":"Adamczuk","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025082607522332800_fcaf207-B65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fneur.2015.00179","article-title":"A practical guide to immunoassay method validation","volume":"6","author":"Andreasson","year":"2015","journal-title":"Front Neurol"},{"issue":"5","key":"2025082607522332800_fcaf207-B66","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/acn3.51553","article-title":"Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer\u2019s disease","volume":"9","author":"De Meyer","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2025082607522332800_fcaf207-B67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","article-title":"Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis","volume":"12","author":"De Meyer","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"38","key":"2025082607522332800_fcaf207-B68","doi-asserted-by":"crossref","first-page":"14615","DOI":"10.1073\/pnas.0803652105","article-title":"Gender differences in human cortical synaptic density","volume":"105","author":"Alonso-Nanclares","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2025082607522332800_fcaf207-B69","doi-asserted-by":"crossref","first-page":"e12492","DOI":"10.1002\/dad2.12492","article-title":"Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer\u2019s disease","volume":"15","author":"Ally","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"2025082607522332800_fcaf207-B70","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025082607522332800_fcaf207-B71","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/brain\/awac128","article-title":"Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer\u2019s disease","volume":"146","author":"Stevenson-Hoare","year":"2023","journal-title":"Brain"},{"issue":"1","key":"2025082607522332800_fcaf207-B72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"2","key":"2025082607522332800_fcaf207-B73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2025082607522332800_fcaf207-B74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41398-024-02837-8","article-title":"Preliminary evidence for preserved synaptic density in late-life depression","volume":"14","author":"Vande Casteele","year":"2024","journal-title":"Transl Psychiatry"},{"issue":"1","key":"2025082607522332800_fcaf207-B75","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41467-019-09562-7","article-title":"Lower synaptic density is associated with depression severity and network alterations","volume":"10","author":"Holmes","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"2025082607522332800_fcaf207-B76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jamia.2001.0080443","article-title":"An integrated software suite for surface-based analyses of cerebral cortex","volume":"8","author":"Van Essen","year":"2001","journal-title":"J Am Med Inform Assoc"},{"key":"2025082607522332800_fcaf207-B77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol Neurodegener"},{"key":"2025082607522332800_fcaf207-B78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2018.08.029","article-title":"APOE \u025b4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer\u2019s disease","volume":"685","author":"Wang","year":"2018","journal-title":"Neurosci Lett"},{"issue":"1","key":"2025082607522332800_fcaf207-B79","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-018-0407-6","article-title":"Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer\u2019s disease","volume":"10","author":"Zhang","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"2025082607522332800_fcaf207-B80","doi-asserted-by":"crossref","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","article-title":"Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease","volume":"95","author":"Tible","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"2025082607522332800_fcaf207-B81","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","article-title":"Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease","volume":"14","author":"Sutphen","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2025082607522332800_fcaf207-B82","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/jnnp-2021-328646","article-title":"CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer\u2019s disease","volume":"93","author":"Halbgebauer","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025082607522332800_fcaf207-B83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13195-023-01300-y","article-title":"Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias","volume":"15","author":"Bentivenga","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"2025082607522332800_fcaf207-B84","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","article-title":"Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease","volume":"5","author":"Galasko","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"2025082607522332800_fcaf207-B85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","article-title":"\u03b1-Synuclein in synaptic function and dysfunction","volume":"46","author":"Sharma","year":"2023","journal-title":"Trends Neurosci"},{"issue":"1","key":"2025082607522332800_fcaf207-B86","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-022-01038-z","article-title":"P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles","volume":"14","author":"Wesenhagen","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2025082607522332800_fcaf207-B87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-021-00861-0","article-title":"VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome","volume":"13","author":"Lle\u00f3","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2025082607522332800_fcaf207-B88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2021.08.002","article-title":"Neurogranin as biomarker in CSF is non-specific to Alzheimer\u2019s disease dementia","volume":"108","author":"Willemse","year":"2021","journal-title":"Neurobiol Aging"},{"issue":"3","key":"2025082607522332800_fcaf207-B89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","article-title":"Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: A longitudinal study","volume":"17","author":"Gordon","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"2025082607522332800_fcaf207-B90","doi-asserted-by":"crossref","first-page":"fcab158","DOI":"10.1093\/braincomms\/fcab158","article-title":"Looking beneath the surface: The importance of subcortical structures in frontotemporal dementia","volume":"3","author":"Bocchetta","year":"2021","journal-title":"Brain Commun"},{"issue":"1","key":"2025082607522332800_fcaf207-B91","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-200065","article-title":"Amyloid-\u03b2 peptides disrupt interactions between VAMP-2 and SNAP-25 in neuronal cells as determined by FRET\/FLIM","volume":"77","author":"Sharda","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2025082607522332800_fcaf207-B92","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.113562","article-title":"Fusion protein vesicle-associated membrane protein 2 is implicated in IFN-gamma-induced piecemeal degranulation in human eosinophils from atopic individuals","volume":"107","author":"Lacy","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2025082607522332800_fcaf207-B93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00418-015-1310-x","article-title":"SNAP-25 is abundantly expressed in enteric neuronal networks and upregulated by the neurotrophic factor GDNF","volume":"143","author":"Barrenschee","year":"2015","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"2025082607522332800_fcaf207-B94","doi-asserted-by":"crossref","first-page":"e12285","DOI":"10.1002\/dad2.12285","article-title":"Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia","volume":"14","author":"Thijssen","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"2025082607522332800_fcaf207-B95","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40035-021-00275-w","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia","volume":"10","author":"Zhu","year":"2021","journal-title":"Transl Neurodegener"},{"issue":"2","key":"2025082607522332800_fcaf207-B96","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: A prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"2025082607522332800_fcaf207-B97","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12916-024-03418-8","article-title":"Peripheral GFAP and NfL as early biomarkers for dementia: Longitudinal insights from the UK Biobank","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"2025082607522332800_fcaf207-B98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neures.2022.09.007","article-title":"Astrocytes regulate neuronal network activity by mediating synapse remodeling","volume":"187","author":"Kim","year":"2023","journal-title":"Neurosci Res"},{"issue":"9","key":"2025082607522332800_fcaf207-B99","doi-asserted-by":"crossref","first-page":"a020370","DOI":"10.1101\/cshperspect.a020370","article-title":"Astrocytes control synapse formation, function, and elimination","volume":"7","author":"Chung","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"2025082607522332800_fcaf207-B100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","article-title":"Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders","volume":"24","author":"Brandebura","year":"2023","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"2025082607522332800_fcaf207-B101","doi-asserted-by":"crossref","first-page":"e164919","DOI":"10.1172\/JCI164919","article-title":"Astroglial toxicity promotes synaptic degeneration in the thalamocortical circuit in frontotemporal dementia with GRN mutations","volume":"133","author":"Marsan","year":"2023","journal-title":"J Clin Invest"},{"issue":"11","key":"2025082607522332800_fcaf207-B102","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","article-title":"Tau oligomer-containing synapse elimination by microglia and astrocytes in Alzheimer disease","volume":"80","author":"Taddei","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"2025082607522332800_fcaf207-B103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","article-title":"Combination of plasma amyloid beta(1-42\/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","volume":"12","author":"Verberk","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"2025082607522332800_fcaf207-B104","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"12","key":"2025082607522332800_fcaf207-B105","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","article-title":"Alzheimer\u2019s disease neuroimaging initiative (ADNI). Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A\u03b2-PET and cognition","volume":"92","author":"Rauchmann","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2025082607522332800_fcaf207-B106","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2025082607522332800_fcaf207-B107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2013.03.019","article-title":"Soluble amyloid precursor protein \u03b1 and \u03b2 in CSF in Alzheimer\u2019s disease","volume":"1513","author":"Brinkmalm","year":"2013","journal-title":"Brain Res"},{"issue":"1","key":"2025082607522332800_fcaf207-B108","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/dad2.12179","article-title":"Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer\u2019s disease","volume":"13","author":"Nilsson","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"2025082607522332800_fcaf207-B109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-022-00534-y","article-title":"Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration","volume":"17","author":"Cervantes Gonz\u00e1lez","year":"2022","journal-title":"Mol Neurodegener"},{"key":"2025082607522332800_fcaf207-B110","doi-asserted-by":"crossref","first-page":"117877","DOI":"10.1016\/j.neuroimage.2021.117877","article-title":"Synaptic density in healthy human aging is not influenced by age or sex: A 11C-UCB-J PET study","volume":"232","author":"Michiels","year":"2021","journal-title":"Neuroimage"},{"issue":"10","key":"2025082607522332800_fcaf207-B111","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/mds.29570","article-title":"Mild motor signs in healthy aging are associated with lower synaptic density in the brain","volume":"38","author":"Van Cauwenberge","year":"2023","journal-title":"Mov Disord"},{"issue":"12","key":"2025082607522332800_fcaf207-B112","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1002\/alz.14327","article-title":"SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE \u025b4\/\u025b4 homozygotes","volume":"20","author":"Snellman","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2025082607522332800_fcaf207-B113","doi-asserted-by":"crossref","first-page":"fcae107","DOI":"10.1093\/braincomms\/fcae107","article-title":"Synaptic density patterns in early Alzheimer\u2019s disease assessed by independent component analysis","volume":"6","author":"Fang","year":"2024","journal-title":"Brain Commun"},{"key":"2025082607522332800_fcaf207-B114","doi-asserted-by":"crossref","first-page":"1380561","DOI":"10.3389\/fnagi.2024.1380561","article-title":"SV2A PET imaging in human neurodegenerative diseases","volume":"16","author":"Bavarsad","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"2025082607522332800_fcaf207-B115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jagp.2012.10.019","article-title":"A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression","volume":"21","author":"Sexton","year":"2013","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"2025082607522332800_fcaf207-B116","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1038\/s41380-023-02285-8","article-title":"Effects of escitalopram on synaptic density in the healthy human brain: A randomized controlled trial","volume":"28","author":"Johansen","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"6","key":"2025082607522332800_fcaf207-B117","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.tpj.6500135","article-title":"Differential expression of VAMP2\/synaptobrevin-2 after antidepressant and electroconvulsive treatment in rat frontal cortex","volume":"2","author":"Yamada","year":"2002","journal-title":"Pharmacogenomics J"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf207\/63362353\/fcaf207.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/4\/fcaf207\/63362353\/fcaf207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/4\/fcaf207\/63362353\/fcaf207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:52:40Z","timestamp":1756209160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf207\/8150934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf207","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf207"}}